Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…
For patients with rheumatoid arthritis (RA), analyzing immune cell diversity in peripheral blood revealed five major immunotype groups, each exhibiting a different response to various biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). This is according to a 2024 study published in Annals of the Rheumatic Disease that aimed to stratify the patients based on…
Arthritis Care & Research (AC&R), a peer-reviewed journal published monthly, comprises original research, review articles and editorials that “move clinical research and practice forward in a meaningful way,” according to AC&R Editor-in-Chief Kelli D. Allen, PhD. That includes research on evidence-based practice; clinical problems; practice guidelines; educational, social, and public health issues; health economics and…
Maternal Health Insights in Patients with SLE The impact of pregnancy readiness on lupus activity, maternal mental health & pregnancy outcomes By Ceshae Harding, MD, & Megan Clowse, MD, MPH Why was this study done? Patients with systemic lupus erythematosus (SLE) who are pregnant have increased risks of risks maternal and fetal mortality, preeclampsia and…
Objective We aimed to identify clinical and demographic features associated with the interval between the appearance of psoriasis and the onset of psoriatic arthritis (PsA). Methods We identified patients with psoriasis and PsA diagnoses from our tertiary care psoriatic disease biorepository: a longitudinal, real-world database including clinical information and patient-reported outcomes. We used a multivariable,…
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…
Reviewing the research presented at ACR Convergence 2024.
Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.